Short-term response of macular oedema to intravitreal bevacizumab

British Journal of Ophthalmology

Volumn 93, Issue 8, 2009, Pages 1033-1036

  Welch, D E ^a   Elmariah, H ^a   Peden, M C ^a   Adams, S G ^a   Ratnakaram, R ^a   Kaushal, S ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS; MACULA LUTEA; MACULAR DEGENERATION; MACULAR EDEMA; MIDDLE AGED; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY; YOUNG ADULT;

EID: 68049109126     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.148874     Document Type: Article

References (25)

1. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111-118
2. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611. (Pubitemid 39099316)
3. Joussen A, Murata T, Tusjikawa A, et al. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001;158:147-152 (Pubitemid 32096479)
4. Roberts W, Palade G. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 1997;57:765-772 (Pubitemid 27085664)
5. Antonetti D, Barber A, Hollinger L, et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999;274:23463-23467 (Pubitemid 129529185)
6. Qu H, Nagy J, Senger D, et al. Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the adluminal plasma membrane and vesiulovacuolar organelles of tumor microvascular endothelium. J Histochem Cytochem 1995;43:381-389
7. Adamis A, Miller J, Bernal M, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-450 (Pubitemid 24307211)
8. Aiello L, Pierce E, Foley E, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-10461
9. Aiello L, Avery R, Arrigg P, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Engl J Med 1994;331:1480-1487 (Pubitemid 24356306)
10. Tripathi R, Li J, Tripathi B, et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 1998;105:232-237 (Pubitemid 28090825)
11. Lashkari K, Hirose T, Yazdany J, et al. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol 2000;156:1337-1344 (Pubitemid 30660011)
12. Kvanta A, Algvere P, Berglin L, et al. Subfoveal fibrovascular membranes in agerelated macular degeneration express vascular endothelial growth factor. Ophthalmol Vis Sci 1996;37:1929-1934 (Pubitemid 26324159)
13. Lopez P, Sippy B, Lambert M, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised agerelated macular degeneration-related membranes. Invest Ophthalmol Vis Sci 1996;37:855-868 (Pubitemid 26110436)
14. Otani A, Takagi H, Oh H, et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvas Res 2002;64:162-169 (Pubitemid 34713242)
15. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000;41:2514-2522 (Pubitemid 30624378)
16. Davidson JA, Ciulla TA, McGill JB, et al. How the diabetic eye loses vision. Endocr 2007;32:107-116
17. Michels S, Rosenfeld P, Puliafito C, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047 (Pubitemid 40797459)
18. Fraser-Bell S, Kaines A, Hykin PG. Update on treatments for diabetic macular edema. Curr Opin Ophthalmol 2008;19:185-189
19. Rosenfield P, Moshfeghi A, Puliafito C. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:270-271 (Pubitemid 41073112)
20. Grisanti S, Ziemssen F. Bevacizumab: off-label use in ophthalmology. Indian J Ophthalmol 2007;55:417-420
21. Bermingham-McDonogh O, McCabe K, Reh T. Effects of GGF/neuregulins on neuronal survival and neurite outgrowth correlate with erbB2/neu expression in developing rat retina. Development 1996;122:1427-1438 (Pubitemid 26159633)
22. Shahar J, Avery R, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-269 (Pubitemid 44318177)
23. Huang D, Swanson E, Lin C, et al. Optical coherence tomography. Science 1991;254:1178-1181
24. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-1867
25. 125I-labelled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27:536-543